blog

Entry into the digitization-governed arena to be witnessed by the Immune Checkpoint Inhibitors Market from 2018-2028, reaching US$ 35 Bn

 The Immune Checkpoint Inhibitors Market is expected to be worth US$ 35 Bn by the year 2028, at a CAGR of 14.6% between 2018-2028. Digital health is into occupation of a noteworthy position in our lives, thereby rendering it a significant tool in the medical device trends going forward. This would be the overall outlook of the healthcare vertical in the forecast period.

Attributed to growing demand for the development of biologics targeting cancer therapy, PMR predicts that the immune checkpoint inhibitors will present lucrative opportunities to investors in the near future – as quoted by a research expert at Persistence Market Research (Healthcare & Life Sciences).

Get Going With Sample Of Immune Checkpoint Inhibitors Market Report! https://www.persistencemarketresearch.com/samples/20122

Expanding at a booming CAGR of 14.6%, the global market for immune checkpoint inhibitors market is expected to reach a value beyond US$ 35 Bn over 2018-2026. The growing prevalence of various types of cancers and expanding healthcare expenditure will remain the most prominent drivers of the immune checkpoint inhibitors market over the forecast period.

Company Profiles:

  • AstraZeneca Plc.
  • Bristol-Myers Squibb Co.
  • Roche Holding AG
  • Incyte Corporation
  • Merck & Co., Inc.
  • Merck KGaA
  • Sanofi
  • Novartis AG

immune-checkpoint-inhibitors-market.jpg

Besides cancer prevalence, increasing FDA approvals and growing use of immune-oncology products in treating cancers will also push the demand for immune checkpoint inhibitors in the near future. However, high price point associated with both drug development and treatment will continue to restrict adoption. Frequently observed last stage failure will also remain a major concern in the long run.

“Our extensive company share analysis predicts that the top two players in the global immune checkpoint inhibitors market currently hold a massive revenue share of over 95%. Based on the exhaustive assessment of each drug class in the global immune checkpoint inhibitors market, we arrived at the forecast that the PD-1 will continue dominance in the market, primarily attributed to rapid FDA approvals to PD-1 products,” explained an expert senior research analyst working with the healthcare and life sciences domain at Persistence Market Research.

How About Re-Inventing The Methodical Wheel In The Immune Checkpoint Inhibitors Market? Switch Over To The “Methodology” Tab! https://www.persistencemarketresearch.com/methodology/20122

FDA Approvals Continue to Encourage North American Market for Immune Checkpoint Inhibitors

North America is likely to continue monopoly in the global market for immune checkpoint inhibitors with over 65% share of the total market revenue. Large number of FDA approvals, expanding application base in treatments for various cancer types, and increasing combination drug approvals will play a pivotal role in shaping the market for immune checkpoint inhibitors in North America.

According to PMR’s regional analysis of global immune checkpoint inhibitors market, Asia Pacific will demonstrate vigorous growth throughout the projection period – at the double digit CAGR of over 17%.

High Potential Combination Therapies to Open New Doors of Opportunities

With a strong reference post success of the promising results delivered by Bristol-Myers...

Do you already have an account? Log in here

Join the discussion

0 comments

To read and post comments you need to login or register